Suppr超能文献

基于传导热的膀胱内热化疗:丝裂霉素 C 在浅表性移行细胞癌患者中的首次药代动力学研究。

Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.

机构信息

Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Corso Raffaello 31, 10125, Turin, Italy,

出版信息

Cancer Chemother Pharmacol. 2014 Mar;73(3):503-9. doi: 10.1007/s00280-014-2381-4. Epub 2014 Jan 18.

Abstract

PURPOSE

To evaluate, for the first time, the mitomycin C (MMC) pharmacokinetics during intravesical hyperthermia treatment based on conductive heat and the stability and recovery of the drug at the end of the instillation period.

METHODS

Eleven patients with recurrent intermediate-risk superficial transitional cell carcinoma of the bladder were treated weekly for six cycles with intravesical MMC (40 mg MMC in 50 ml) in local hyperthermia (45 °C) with Unithermia(®) system. Each instillation lasted 45 min, with the solution being replaced after the first 22 min. The MMC recovery at the end of the two instillation period and the plasmatic pharmacokinetics of MMC were evaluated by high-pressure liquid chromatography.

RESULTS

Nine patients completed all the six planned cycles, whereas two patients missed the last cycle because of allergic reactions. No other systemic toxicity was observed, and the local toxicities were mild. Median MMC concentration in the instillation residual solution decreases from the initial 0.8 to 0.22 mg/ml for the 0-22-min instillation period and to 0.38 mg/ml for the 22-45-min instillation period; the median percentage of MMC recovered after instillation was 66.2 and 99.6, respectively. In all patients, MMC plasmatic C max resulted considerably lower than the toxic threshold (400 ng/ml).

CONCLUSIONS

The MMC is stable during the instillation, and its absorption occurs mainly during the first minutes of the treatment. The plasmatic MMC concentration is always well below the threshold level for myelosuppression, as confirmed by the total lack of hematological toxicity evidenced by the patients. In order to evaluate the efficacy of the treatment performed with UniThermia(®) in reducing the disease recurrence rate in short- and long-term follow-up, we are currently carrying out a clinical multicentric study involving a larger number of patients.

摘要

目的

首次评估基于传导热的膀胱内热疗时丝裂霉素 C(MMC)的药代动力学,以及灌流结束时药物的稳定性和回收率。

方法

11 例复发性中危浅表性膀胱移行细胞癌患者,每周接受 6 个周期的腔内 MMC(40mg MMC 溶于 50ml 溶液中)治疗,同时采用 Unithermia(®)系统进行局部热疗(45°C)。每次灌流持续 45 分钟,前 22 分钟更换溶液。通过高压液相色谱法评估两次灌流结束时的 MMC 回收率和 MMC 的血浆药代动力学。

结果

9 例患者完成了所有 6 个计划周期,而 2 例患者因过敏反应错过了最后一个周期。未观察到其他全身毒性,局部毒性轻微。初始 0-22 分钟灌流期间,灌流残留液中 MMC 浓度中位数从 0.8 降至 0.22mg/ml,22-45 分钟灌流期间降至 0.38mg/ml;灌流后 MMC 回收率中位数分别为 66.2%和 99.6%。在所有患者中,MMC 血浆 C max 明显低于毒性阈值(400ng/ml)。

结论

MMC 在灌流过程中稳定,其吸收主要发生在治疗的最初几分钟内。MMC 血浆浓度始终明显低于引起骨髓抑制的阈值水平,这从患者未出现任何血液学毒性得到证实。为了评估 UniThermia(®)治疗在降低短期和长期随访中疾病复发率方面的疗效,我们目前正在进行一项涉及更多患者的临床多中心研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验